Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Results: Revenue...